文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

放疗后局部复发前列腺癌的基因组与转录组特征

Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-09-29

该研究对36例患者的41个活检证实的放疗后局部复发前列腺癌(LRR-PCa)肿瘤进行靶向DNA测序和RNA表达分析,并与未治疗患者及复发时Gleason分级匹配患者比较。结果显示LRR-PCa在29个前列腺癌相关基因中单核苷酸变异显著富集,Decipher评分更高、基底亚型比例更高、雄激素受体活性更低,提示其具有独特的基因组和转录组景观。

要点

  • LRR-PCa在FAT1、RAD51B、POLQ、KMT2C、BRCA2、ATRX、BRCA1等DNA修复和侵袭相关基因中SNV频率显著高于未治疗患者。

核心结论

  • LRR-PCa具有区别于原发前列腺癌的独特基因组和转录组景观,表现为侵袭性和DNA修复相关基因SNV富集、Decipher评分更高、基底亚型更多及雄激素受体活性更低。

研究设计与样本

  • 研究对36例患者的41个活检证实的LRR-PCa肿瘤进行靶向DNA测序和RNA表达分析,复发中位间隔84个月(IQR 70-124个月)。
  • 基因组改变频率与癌症基因组图谱中496例未治疗患者比较,转录组数据与Decipher基因组资源中按复发时Gleason分级匹配的22,320例患者比较。

临床怎么用

  • 对于放疗后局部复发前列腺癌,可考虑评估DNA修复基因变异和转录组特征以辅助风险分层。
  • 复发时病理分级升高常见,应重视再活检及分子检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The biology of locally radiorecurrent prostate cancer (LRR-PCa) is poorly understood. METHODS AND MATERIALS: We sought to explore the genomic and transcriptomic landscape of LRR-PCa with targeted DNA sequencing and RNA expression analysis from 41 biopsy-proven LRR-PCa tumors from 36 unique patients who had a recurrence at a median interval of 84 months (IQR, 70-124 months). Genomic alteration frequencies and transcriptomic data were compared between the LRR-PCa cohort and treatment-naïve patients from the Cancer Genome Atlas (genomic; n = 496) and Gleason grade-at-recurrence-matched patients from the Decipher Genomics Resource for Intelligent Discovery (transcriptomic; n = 22,320). RESULTS: Twenty-five patients (69%) had pathologic upgrading at recurrence (17% vs 64% with Gleason grade 4-5 disease; P < .001). The LRR-PCa cohort demonstrated significantly greater single-nucleotide variations in 29 genes known to be associated with prostate cancer, including several associated with increased aggressiveness and DNA repair: FAT1 (58.5% vs 1.0%), RAD51B (36.6% vs 0.4%), POLQ (34.1% vs 1.4%), KMT2C (34.1% vs 4.9%), BRCA2 (29.3% vs 1.8%), ATRX (26.8% vs 0.8%), and BRCA1 (24.4% vs 0.4%) (Pvalues < .001 for all). The LRR-PCa cohort had a significantly higher Decipher score (median, 0.80 vs 0.66; P = .05) and demonstrated significantly greater basal subtype based on PAM50 (56% vs 20%; P < .001) and lower androgen receptor activity (61% for LRR vs 9%; P < .001). CONCLUSIONS: Overall, these results suggest that LRR-PCa has a distinct genomic and transcriptomic landscape from de novo prostate cancer. Specifically, LRR-PCa has an enrichment in SNVs in genes associated with tumor aggressiveness and/or DNA repair, has higher Decipher scores, a more basal subtype, and has transcriptomic evidence of lower androgen receptor activity and loss of tumor suppressor genes.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Neilsen BK, Huang RR, Valle LF, et al. Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 41105052. doi:10.1016/j.ijrobp.2025.09.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。